Juanbi Qianggu Formula inhibits fibroblast-like synovicytes activation via repressing LncRNA ITSN1-2 to promote RIP2 K48 ubiquitination

Yanqin Bian, Fang Li, A Xinyu, Xiang Zheng, Nanshan Ma, Jianye Wang, Boran Cao, Pengfei Xin, Xuan Cheng, Chang Liu, Bei Xiang, Jun Shen, Q Lu, Lianbo XiaoChinese 2025 · DOI

TL;DR

This study reveals how a traditional Chinese medicine, Juanbi Qianggu Formula (JBQG), combats rheumatoid arthritis (RA) by targeting a specific molecular pathway involving a long non-coding RNA (lncRNA) called ITSN1-2. JBQG effectively reduces inflammation and joint damage by disrupting the ITSN1-2/miR-6823-3p/PELI3/RIP2 axis, offering a novel therapeutic strategy for RA.

What Problem Does This Paper Address?

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation and destruction of the joints, leading to significant disability. While current treatments exist, they often have limitations and don't fully address the complex mechanisms driving RA. Fibroblast-like synovicytes (FLS) play a crucial role in RA pathogenesis by promoting inflammation and joint destruction. Previous research identified lncRNA ITSN1-2 as a key player in RA, promoting FLS proliferation and survival by activating the NOD2/RIP2 signaling pathway. However, the precise molecular mechanisms by which traditional Chinese medicine (TCM) like Juanbi Qianggu Formula (JBQG) exerts its anti-arthritic effects, particularly in relation to ITSN1-2, remained unclear. This paper aims to elucidate how JBQG modulates the ITSN1-2-mediated NOD2/RIP2 pathway to combat RA.

Methods

The researchers employed a multi-pronged approach:

  • Human Tissue Analysis: Synovial tissues from RA and osteoarthritis (OA) patients were analyzed to assess the expression of ITSN1-2, NOD2, and PELI3, and to correlate ITSN1-2 levels with disease severity markers.
  • TCM Component Analysis: Mass spectrometry was used to identify the active components absorbed into the bloodstream after JBQG administration in rats.
  • In Vitro Experiments:
    • Cell Culture: Primary FLS and the MH7A cell line were used to study the effects of JBQG and ITSN1-2 modulation on cell proliferation, migration, and invasion.
  • Molecular Assays: Real-time PCR was used to measure gene and lncRNA expression. Dual-luciferase reporter assays and FISH assays were employed to investigate the interactions between ITSN1-2, miR-6823-3p, and PELI3. Co-immunoprecipitation (Co-IP) and Western blotting were used to examine protein levels and ubiquitination.
  • Animal Model: A collagen-induced arthritis (CIA) rat model was established to evaluate the therapeutic efficacy of JBQG, particularly in the context of ITSN1-2 overexpression. Histopathological examination and serum cytokine analysis were performed.

Datasets

  • Human Synovial Tissues: Samples were collected from 24 RA patients and 20 OA patients.
  • Rat Serum and Knee Joint Samples: Collected from a CIA rat model treated with JBQG.
  • Blood-Absorbed Components: Identified in rat serum after JBQG administration.

Key Insights and Ideas

  • ITSN1-2 as a Central Player: The study strongly implicates lncRNA ITSN1-2 as a key driver of synovial inflammation and joint damage in RA, with its expression correlating with disease severity.
  • JBQG's Dual Action: JBQG doesn't just target one aspect of the disease; it acts both upstream by reducing ITSN1-2 levels and downstream by promoting RIP2 degradation.
  • ceRNA Mechanism Unveiled: ITSN1-2 acts as a "molecular sponge" for miR-6823-3p, a mechanism known as competitive endogenous RNA (ceRNA). By sequestering miR-6823-3p, ITSN1-2 indirectly leads to increased PELI3 expression.
  • PELI3's Role in RIP2 Regulation: PELI3, an E3 ubiquitin ligase, is crucial for promoting RIP2 ubiquitination, specifically K48-linked ubiquitination, which leads to RIP2 degradation.
  • JBQG's Precision Targeting: JBQG's ability to modulate ITSN1-2 and subsequently influence the PELI3-RIP2 axis suggests a potential for precision medicine approaches in RA, particularly for patients with high ITSN1-2 expression.
  • TCM Synergy: The findings provide a mechanistic basis for combining TCM like JBQG with conventional therapies (e.g., NOD2 inhibitors) for enhanced therapeutic effects.

Key Results

  • Elevated ITSN1-2 in RA: ITSN1-2 and NOD2 expression were significantly upregulated in RA synovial tissues compared to OA, while PELI3 was downregulated.
  • ITSN1-2 and Disease Severity: ITSN1-2 levels positively correlated with RA disease activity markers (DAS28-ESR, ESR, CRP) and knee joint bone damage scores.
  • JBQG Inhibits FLS Activity: JBQG treatment suppressed the proliferation, migration, and invasion of FLS cells.
  • ITSN1-2/miR-6823-3p/PELI3 Axis: Bioinformatic analysis and experimental validation confirmed that ITSN1-2 sponges miR-6823-3p, leading to PELI3 upregulation.
  • RIP2 K48 Ubiquitination: JBQG treatment selectively enhanced RIP2 K48-linked ubiquitination, promoting RIP2 degradation and inhibiting the NOD2/RIP2 signaling pathway.
  • Reduced Inflammation and Damage: JBQG significantly downregulated pro-inflammatory markers (p-IKB, p65, MMP3) and reduced FLS invasion.
  • Therapeutic Efficacy in CIA Model: In the CIA rat model, JBQG treatment effectively reduced joint synovitis and cartilage damage, especially in the context of ITSN1-2 overexpression.

Limitations and Future Work

  • Bone Remodeling: The study acknowledges that ITSN1-2's direct role in bone remodeling needs further investigation, although FLS-derived MMPs are implicated.
  • FLS Subpopulations: The differential expression of ITSN1-2 in various FLS subpopulations (M1 vs. M2) requires further study using single-cell RNA-seq.
  • In Vitro Bone Metabolism Models: The authors suggest using co-culture models of FLS with osteoblasts/osteoclasts to dissect ITSN1-2's direct effects on bone destruction.
  • Clinical Translation: More data are needed to assess JBQG's efficacy in RA patients with high ITSN1-2 plasma levels in Phase II studies.
  • Long-Term Safety and Biomarker Validation: Future research should focus on long-term safety assessments and clinical biomarker validation to advance RA treatment strategies.
  • TCM-Biologic Combination: The study provides a theoretical basis for combining TCM with biologics, which warrants further investigation.

Summary updated

Abstract

This study demonstrates that JBQG exerts potent anti-arthritic effects in RA therapy through dual regulatory mechanisms targeting the lncRNA ITSN1-2/miR-2683-3p/PELI3/RIP2 axis.
BibTeX
@inproceedings{bian2025juanbi,
  author = {Yanqin Bian and Fang Li and A Xinyu and Xiang Zheng and Nanshan Ma and Jianye Wang and Boran Cao and Pengfei Xin and Xuan Cheng and Chang Liu and Bei Xiang and Jun Shen and Q Lu and Lianbo Xiao},
  title = {{Juanbi Qianggu Formula inhibits fibroblast-like synovicytes activation via repressing LncRNA ITSN1-2 to promote RIP2 K48 ubiquitination}},
  booktitle = {Chinese},
  year = {2025},
  doi = {10.1186/s13020-025-01164-4},
}
Figure